Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 nov 2013 - 07:38
Statutaire naam
Galapagos NV
Titel
Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma
Bericht
• Identification and validation of novel targets in scleroderma
• Will leverage Galapagos' SilenceSelect® platform and unique human skin models
Mechelen (Belgium); 12 November 2013 - Galapagos NV (Euronext: GLPG) announced today that its subsidiary BioFocus signed a 3-year collaboration agreement with Biogen Idec focused on the identification and validation of novel targets in scleroderma.
Galapagos' service division BioFocus will use its SilenceSelect® platform and unique human skin models to deliver new assays and identify disease-modifying targets in scleroderma to Biogen Idec. Under the terms of the agreement, BioFocus will receive an upfront payment, FTE funding, and will be eligible to receive success payments for target discovery milestones to be delivered by BioFocus and development milestones achieved by Biogen Idec. The total value of this collaboration to BioFocus could reach $31 million.
Datum laatste update: 18 december 2025